A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer (NCT04982926) | Clinical Trial Compass
TerminatedPhase 1
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Stopped: After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.
United States, France29 participantsStarted 2021-09-16
Plain-language summary
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted
* Have adequate organ function
* ECOG PS 0-1
Dose Escalation:
* Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO
* Any solid tumor with EGFR and / or HER2 aberration
Dose Expansion:
* Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma)
* Cohort A: Non-small cell lung cancer (NSCLC)
* Cohort B: HER2 positive breast cancer
* Cohort C: Recurrent or refractory glioblastoma
* Cohort D: Other solid tumors with EGFR or HER2 aberrations
Exclusion Criteria:
* Non-stable brain metastases
* Have significant cardiovascular disorder
* Have not recovered from prior cancer treatment
* A serious illness or medical condition
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.